JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.030
+0.130 (6.84%)
At close: Mar 10, 2026
-1.46%
Market Cap 770.71M
Revenue (ttm) 194.77M
Net Income (ttm) -676.78M
Shares Out 405.64M
EPS (ttm) -1.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,949,500
Average Volume 1,006,625
Open 1.910
Previous Close 1.900
Day's Range 1.900 - 2.060
52-Week Range 1.260 - 6.440
Beta 1.97
RSI 40.27
Earnings Date Mar 25, 2026

About HKG:2126

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapy for use in the treatment of a range of hematological ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 292
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2126
Full Company Profile

Financial Performance

In 2024, HKG:2126's revenue was 158.22 million, a decrease of -8.99% compared to the previous year's 173.86 million. Losses were -590.62 million, -23.10% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.